Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis
NCT: NCT07556237 · NOT_YET_RECRUITING
Brief Summary
Gastroparesis is a disorder characterized by delayed gastric emptying and symptoms including nausea, vomiting, and abdominal pain. Gastric electrical stimulation (GES) using the implanted Enterra™ neurostimulator is FDA-approved to treat nausea and vomiting but its impact on abdominal pain has not been well studied. This study evaluates whether alternative programming parameters of the Enterra™ device can reduce abdominal pain in patients with gastroparesis. Participants with an existing Enterra™ device will be randomized to one of three stimulation settings and followed for assessment of pain, gastrointestinal symptoms, quality of life, and medication use.
Frequently Asked Questions
What is Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis?
Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis is a clinical trial registered under NCT07556237. Current status: NOT_YET_RECRUITING.
What is the status of NCT07556237?
The current status of NCT07556237 (Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis) is: NOT_YET_RECRUITING.
When did Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis start?
Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis started on 2026-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.